This paper highlights our experience of the transfer of hydrodynamic gene therapy (HGT) from the large animal, the pig, into clinical practice. The modification of balloon catheters and the development of a minimally invasive technique to allow selective isolation of liver segments for HGT in the large animal and human are described. Finally, our preliminary results from a phase I clinical study of HGT for thrombopoietin (TPO) in cirrhotic patients with thrombocytopenia are discussed. Based on these provisional data, minimally invasive selective HGT of liver segments appears to be technically safe, but further work is required to optimize the efficiency of gene transfer in order to achieve clinical benefit.
Introduction
The introduction of gene therapy into clinical practice has been limited by technical issues, such as concerns over safety (immunogenicity and carcinogenicity), insufficient transfer of genetic material and unsustained expression of transferred genes. Hydrodynamic gene therapy (HGT) initially described in mice 1,2 appears to be a promising solution with rapid intravenous injection of a large volume of plasmid DNA (pDNA) producing effective gene transfer and expression in the liver. Explanations for the hydrodynamic gene transfer observed have been increase in membrane permeability and endocytic vesicle formation by the hepatocyte. [3] [4] [5] [6] Presently, there is no evidence of toxicity or immune elimination of the transgene product, with in vivo evidence for long-term expression after HGT. 7 The transfer of HGT from the small to large animal model has been problematic with concerns that the massive fluid shifts involved would precipitate heart failure. Therefore, a method where the rapid fluid shifts were isolated to the liver to minimize the systemic upset was developed in the larger animal model of the rabbit. 8 The technique involved isolation of the inferior vena cava (IVC) at laparotomy and injection of pDNA solution between two balloon catheters within the IVC thereby isolating the liver venous outflow. A number of groups are now modifying this approach to HGT in the pig using balloon catheters to isolate the venous outflow of the liver. 9, 10 This paper presents our experience of HGT in the large animal model of the pig. The modification of the balloon catheters and development of a minimally invasive technique to allow selective isolation of liver segments for HGT in the large animal and human are described. Finally, our preliminary results from a phase I clinical study of HGT for thrombopoietin (TPO) 11 in cirrhotic patients with thrombocytopenia are discussed.
Materials and methods

Genetic constructs
Plasmids produced were compliant with Good Laboratory Practice Standards. Plasmids were constructed to express either human TPO (hTPO) or murine TPO (mTPO) or b-galactosidase (LacZ). The plasmids were based on the pCpG vector produced by InvivoGen (San Diego, CA, USA). The pCpG-LacZ, pCpGmTPO (61) and pCpGhTPO (61, 101, 123, 129 and 147) had the human elongation factor 1-a core promoter and were devoid of cytosine-phosphorous-guanine dinucleotides (CpG) motifs. Plasmids were grown in GT115 strain of Escherichia coli (InvivoGen) and extracted with Qiagen Plasmid Maxi Prep (Crawley, Sussex, UK). The plasmid intended for injection was delivered in the form of a lyophilizate diluted in physiological saline solution. Modifications (61, 101, 123, 129 and 147) to the pCpGhTPO were done to try and establish the best performing plasmid in the large animal of the pig. The pCpG101hTPO was finally selected for use in the human clinical study. The pCpG101hTPO is presently awaiting its patent (Cayla, Toulouse, France).
In vivo study: pigs Initial porcine work aimed to reproduce that of Eastman et al., 8 where in the rabbit model, isolation of the hepatic veins was achieved surgically via the open abdomen. To develop a less invasive technique, presently available balloon catheters were used to isolate the liver. Using a 7Fr balloon catheter, it was found that selective access to the left lobe of the pig liver could easily be achieved via the internal jugular vein and right side of the heart ( Figure 1 ). Up to 300 ml of saline could be rapidly injected, under high pressure with no obvious distortion or damage to the liver on ultrasound assessment. This minimally invasive approach for selective delivery of HGT was used throughout the pig experiments.
Twelve female mini white pigs weighing 22-25 kg were used. The pigs were housed in the animal house (Transplantation Foundation, Strasbourg, France) for 2-3 days prior to start of an experiment. In the operating theater suite, two tables for porcine experiments with equipment for assisted mechanical ventilation, control of anesthesia and appropriate monitoring were used. Accessory equipment available was fluoroscopy, ultrasound and angiographic injector pumps. Speed of injection could be regulated to deliver up to 20 ml s
À1
with a pressure injection of up to 1100 psi (51.7 mm Hg).
Under general anesthesia with ketamine the pigs were intubated and ventilated. A venous line was placed in the ear vein. The pigs were placed in the supine position and the right internal jugular vein was exposed. To avoid losing animals unnecessarily an open surgical exposure of the internal jugular vein was used throughout. Percutaneous catheterization would have been technically difficult because of the acute angle of the internal jugular vein on entering the thorax, therefore increasing the risk of complications, such as pneumothorax.
Following insertion in the internal jugular vein, the balloon catheter was advanced under fluoroscopy through the right side of the heart into the IVC and then into the left hepatic vein. The balloon was inflated with 2-4 ml of saline and contrast (70% urograffin) administered via the injection channel. Thereby allowing fluoroscopic confirmation of correct deployment of the balloon catheter and ensuring no venous outflow from the left lobe of the liver back into the IVC before hydrodynamic pDNA injection (Figure 2 ). The balloon catheter was left inflated for 10 min after HGT and then removed.
In total 12 pigs underwent HGT. Blood samples were taken before injection and at various intervals post injection. Standard full blood count and liver biochemistry (bilirubin, aspartate transaminase, alanine transaminase, g-glutamyl transpeptidase, alkaline phosphatase and albumen) was performed. Ultrasound assessment of the liver was performed after hydrodynamic injection. When the animals were killed tru-cut biopsies of the right and left lobes of the liver were taken.
The first two pigs (nos. 1-2) received pCpG-LacZ. Pig 1 was given 12 mg pDNA/200 ml saline administered at 2 ml s
, injection pressure of 900 psi. On day 5 post injection, a tru-cut biopsy was taken of the right and left lobe of the liver and on day 12 tru-cut biopsies were repeated at laparotomy and the animal was killed. Pig 2 received 20 mg pDNA/260 ml saline administered at 20 ml s À1 , injection pressure of 1100 psi. On day 2 post injection tru-cut biopsies of the right and left lobes of the liver were made at laparotomy and the animal was killed. b-Galactosidase staining was then performed on the liver biopsies. Figure 1 Schematic guide of the stent route (black line) used to guide the balloon catheter via the right neck to obtain access to the hepatic veins feeding the left lobe the liver in the pig (JV, jugular vein; SVC, superior vena cava; RH, right heart; PV, portal vein). , 1000 psi and pig 5 received 20 mg pDNA/300 ml saline at 20 ml s À1 , 1000 psi. Animals were killed on day 22 post injection. Blood samples were performed on day 0, before injection and on days 3, 7, 13 and 22, after injection.
Three pigs (nos. 6-8) were injected with hTPO (pCpG101hTPO). All three received 20 mg pDNA/ 260 ml saline at 20 ml s À1 , 1000 psi. Blood samples were performed on day 0, before injection and on days 2, 3, 5, 6, 9, 12, 14 and 17, after injection. One pig was killed on day 6, one on day 12 and one on day 17 post injection.
In the final four pigs (nos. 9-12) alternative plasmids for hTPO were administered. Pigs 9 and 10 received 20 mg pDNA/300 ml saline at 20 ml s À1 , 1000 psi (pCpG123h TPO, pCpG129hTPO, respectively). Pigs 11 and 12 received 50 mg pDNA/300 ml saline at 20 ml s À1 , 1000 psi (pCpG61hTPO and pCpG147hTPO, respectively). All four pigs bled on day 0, before injection, then on days 3, 6, 9 and 15 post injection. Two pigs were killed on day 15 and the remaining two pigs bled on day 22 and were then killed.
Clinical study
A clinical protocol for a dose-escalation phase I study of HGT of hTPO (pCpG101hTPO) in cirrhotic patients with thrombocytopenia was designed. Currently, there is no recombinant TPO protein to correct thrombocytopenia in clinical practice. The study was run by the Faculty of Medicine, Cairo University, Cairo, Egypt where ethical approval had been granted.
Study inclusion criteria were a thrombocyte count o150 Â 10 9 per liter, age 35-75 years, fertile participants able to practice barrier contraception for the duration of the study, Karnofsky performance status X70% and informed consent. Study exclusion criteria were pregnancy, lactation, life threatening illness unrelated to background liver insufficiency, participation in any other clinical trial 30 days prior or during the course of the trial and inability to give informed consent.
Patients recruited to the trial were given local anesthetic at the point where the balloon catheter was introduced into the femoral vein. The presently available balloon catheters used in the porcine experiments were found to be problematic, on grounds of size and circulation escapes during pressurized injection. Therefore, a modified balloon catheter was used for the human HGT (Figure 3) . The modified catheter was navigated into the middle hepatic vein under fluoroscopy. The balloon inflated and contrast (70% urograffin) injected to check correct deployment of the catheter and to ensure no back flow from the isolated segments of the liver into the IVC before hydrodynamic pDNA delivery. The hTPO (pCpG101hTPO) pDNA was diluted in saline and then injected in less than 1 min. The amount of plasmid used per patient varied from 1 to 45 mg and volume of saline used for dilution varied from 50 to 300 ml. The modified balloon catheter was left inflated for 10 min after HGT and then removed. Patients were observed for 2 h post procedure and then discharged. Follow-up consisted of blood samples for standard full blood count and liver biochemistry on day 1 then at 1, 2, 3 and 4 weeks post procedure, which was done on an outpatient basis.
Results
In vivo study: pigs Hydrodynamic injection of reporter plasmid pCpGLacZ. Two pigs were injected with the reporter plasmid pCpG-LacZ. No immediate complications were observed. Blood samples for standard full blood count and liver biochemistry from the animals did not demonstrate any significant abnormality (data not shown). One liver biopsy from the left lobe taken from pig 2 on day 2 post hydrodynamic injection was positive for b-galactosidase with staining appearing to involve endothelial and Kupffer's cells with sparing of hepatocytes (Figure 4) . Overall, the percentage of cells found to be expressing b-galactosidase was low at 5%.
Hydrodynamic injection of murine thrombopoietin plasmid (pCpG61mTPO). Three pigs were injected with the Selective hydrodynamic gene therapy SE Khorsandi et al mTPO plasmid (pCpG61mTPO). All animals tolerated the procedure well without obvious adverse effect. Ultrasound assessment of the liver did not demonstrate any gross changes within the liver. A transient rise in liver transaminases was observed on days 2 and 3 which then returned to normal values, this was not a significant rise compared to baseline transaminases before commencement of HGT. All other liver biochemistry was unaffected (data not shown). In two pigs (pigs 4 and 5) an initial rise in platelet count at day 7 was demonstrated which then declined by day 22 ( Figure 5 ). In pig 3, which had received the mTPO plasmid at a lower injection pressure (750 psi) and speed (2 ml s À1 ), the effect on platelet count was minimal ( Figure 5 ).
Hydrodynamic injection of human thrombopoietin plasmid (pCpG101hTPO, pG123hTPO, pCpG129hTPO, pCpG61hTPO and pCpG147hTPO). All seven pigs tolerated HGT without any obvious adverse effect. Liver ultrasound after hydrodynamic therapy was normal in all cases. In the three pigs (pigs 6-8) that received pCpG101hTPO (20 mg pDNA/260 ml at 20 ml s À1 ), two pigs (pigs 7 and 8) exhibited a dramatic peak in platelet count at day 7 which declined by day 17, while in pig 6 a minimal change in platelet count was observed ( Figure 6 ). In contrast the four animals given pG123hTPO, pCpG129hTPO, pCpG61hTPO or pCpG147hTPO, a modest rise in platelet count, peaking at days 7-9 was observed ( Figure 7 ). In the two animals (pigs 11 and 12) that had received 50 mg pDNA/300 ml saline at 20 ml s À1 , 1000 psi (pCpG61hTPO and pCpG147hTPO, respectively), a persistently elevated platelet count was observed up to day 22 when the animals were killed (Figure 7) .
Clinical study
In total 16 cirrhotic patients with thrombocytopenia were recruited. Patient demographics: median age 52 years (range, 35-60 years), 12 males and 4 females. Etiology of the cirrhosis was either Hepatitis B (n ¼ 1) or C (n ¼ 15). Eleven were classified as child A and five as child B cirrhotics. In 2 out of the 16 patients recruited HGT could not be applied. In one case, the middle hepatic vein was too wide to be occluded by the catheter balloon. In the other case the catheter could not be guided into the middle hepatic vein because of the acute angle between the hepatic vein and supra-hepatic IVC. In the remaining 14 patients there were no technical difficulties in deploying the catheter into the middle hepatic vein and balloon inflation was effective in preventing back flow.
All patients tolerated HGT without any obvious adverse effect. On serial blood analysis, there were no significant changes in liver biochemistry (data not shown). The procedure was well tolerated and in most cases HGT Pig 12 Figure 7 Graphical summary of data from four pigs (pigs 9-12) after hydrodynamic gene therapy with the alternative plasmids for human thrombopoietin (pCpG123hTPO, pCpG129hTPO, pCpG61hTPO and pCpG147hTPO) of platelet count (10 9 per mm 3 ) against time (day). Pigs 9 and 10 received 20 mg pDNA/300 ml saline at 20 ml s
À1
, 1000 psi (pCpG123hTPO and pCpG129hTPO, respectively). Pigs 11 and 12 received 50 mg pDNA/300 ml saline at 20 ml s À1 , 1000 psi (pCpG61hTPO and pCpG147hTPO, respectively).
Selective hydrodynamic gene therapy SE Khorsandi et al produced a transient elevation in platelet count, which was usually evident at day 7. By the end of the 4-week period of follow-up, platelet count had gradually declined back to the original starting level. The results are summarized in Table 1 and Figure 8 .
Discussion
HGT has attracted great interest. Mainly because of the promising initial work in the mouse demonstrating this technique to be safe and have efficient transfer of genetic material. 2 The somewhat brutal hypervolemia that was induced in mice leading to transient heart failure and subsequent retrograde flow of the introduced material into the hepatic veins was not deemed feasible in a large animal. However, the work of Eastman et al. 8 pointed the way forward by working at the organ level using a catheter and from this starting point our experiments were devised.
Initially when undertaking HGT, the major technical problem experienced proved to be the lack of suitable balloon catheters. The approach of cannulating the left hepatic vein through the heart from the right internal jugular vein, a standard radiographic procedure in human medicine, was easy to achieve in the pig but creating a good seal with the balloon catheter to prevent backflow during the high-pressure injection of HGT was problematic. Presently, two other groups are developing catheter-based techniques to apply HGT in the large animal model of the pig. Yoshino et al. 10 approached the problem by catheterizing the hepatic veins and at the same time occluded the hepatic artery and portal vein. However, in their model laparotomy was required to gain inflow control, making this an invasive and complex procedure. Alino et al. 9 on the other hand used unmodified balloon catheters to occlude the hepatic veins but also experienced similar problems with backflow when performing HGT injection.
Based on the experience from the use of unmodified balloon catheters in the pig, a tailor-made balloon catheter was developed to facilitate the application of a minimally invasive technique for HGT in the human liver. Key aspects of the design ensured maintenance of lumen on inflation of the balloon, allowing fast and large volume injection to be performed. Another feature was for the rear diameter of the distal aspect of the balloon, to increase as the pressure rose within the liver in response to hydrodynamic injection, thereby improving the seal and preventing backflow.
The presence of b-galactosidase after the introduction of the LacZ gene into pigs was positive but the distribution of the enzyme in the liver appeared to be limited to the perivascular regions whereas optimally, as seen in mice, extensive involvement of hepatocytes needs to be seen. The TPO gene and its receptor are highly conserved which would be consistent with the expressed TPO whether it was the human or murine form having broad species cross reactivity. However, the evidence for introduction of the TPO gene into the pig as reflected by the change in platelet count was small. The transient derangement in liver transaminases in some animals suggested a degree of liver damage by the hydrodynamic injection though none was evident on US or in the biopsies taken when the pigs were killed (data not shown). In contrast, liver damage in the mouse model is much greater than in the present pig model and success of HGT has been found to be high in the mouse. 2 Suggesting a sufficient degree of damage to the liver is a prerequisite for success with HGT. Potentially this selective technique of liver HGT may not be producing an adequate level and volume of liver injury for optimal results to be observed and more work is required to establish whether the Table 1 Table summarizing changes in platelet count (10  9 per mm 3 ) with time (day) in 14 patients following hydrodynamic injection of human TPO (pCpG101hTPO) using different volumes (ml) and amounts of pDNA (mg) amount of liver injury is a determinant of effective HGT in this model.
These pig experiments do show that it is possible to move HGT into larger animals without any resultant morbidity and mortality. The demonstration that this approach to HGT in the pig was feasible, led to a phase I study of HGT with hTPO in cirrhotic patients with thrombocytopenia. Only with two patients, on anatomical grounds alone, it was not technically possible to deploy the modified balloon catheter. In all other patients, the approach of isolating the hepatic venous outflow from the systemic circulation was achieved, with administration of 1-45 mg pDNA in volumes up to 300 ml with no obvious adverse effects on the patient. All the patients were able to be discharged on the day of HGT and followed up on an outpatient basis. However, a clinically useful elevation of platelet count was not found.
The results presented are disappointing in terms of change in gene expression. Both Yoshino et al. 10 and Alino et al.
9 experienced similar problems of inefficient gene transfer and unpredictability in expression, despite large amounts of pDNA being used. Aspects of HGT to be addressed in future work will need to concentrate on determining the critical aspect behind successful HGT, whether that be volume, speed or pressure of injection and does degree of liver injury predict response. Additional technical aspects to be explored will be whether inflow control is truly needed and if so how this can be achieved easily with thought toward its usability in clinical practice, especially in the application to the diseased liver.
In conclusion, the work presented in this paper demonstrates that HGT established in mice 2 can be modified for use in larger animals and man. In order to popularize and simplify the technique we have tailoredmade a balloon catheter, with which we have experienced no morbidity and mortality, and clinically has the potential to be used on an outpatient basis. Our preliminary results from a phase I clinical study of HGT for TPO in cirrhotic patients with thrombocytopenia are disappointing in terms of clinically beneficial elevation of platelet count. But the clinical study does demonstrate that this approach to minimally invasive selective HGT of liver segments can be done safely in a high-risk group of cirrhotics. However, further work is required to optimize a number of technical aspects of HGT in order to ensure effective, reproducible and lasting change in gene expression in the large animal model of the pig and ultimately in the human subject.
